Thymalin with epitalon
Thymalin with epitalon or epithalamin (Khavinson bioregulator protocol)
Written by Aaron CuhaReviewed Sep 2026
Also known as: Thymalin epithalamin, Khavinson geroprotector protocol, Bioregulator pair
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
This is the one blend on this site with a real study of the combination itself, and the numbers are enormous. It is also unblinded, from one Russian group, never repeated, and the pineal ingredient in the study is not the one sold today.
What people take it for
- Living longer.
- Getting sick less often.
- Immune function in older age.
- Sleep and body clock.
What the trials actually showed
The study followed 266 older people for six to eight years. They got the two peptides during the first two or three years. Colds and chest infections dropped by 2.0 to 2.4 times. Deaths dropped 2.0 to 2.1 times in the thymus peptide group, 1.6 to 1.8 times in the pineal group, and 2.5 times in the group that got both. A separate group who got both every year for six years had a death rate 4.1 times lower than the control group. If those numbers held up, this would be the biggest result on this whole site. Here is why nobody treats it that way. One research group ran it. There is no sign anyone was blinded or randomly assigned. How the control group was picked is not described. And in more than twenty years, no other group anywhere has tried to repeat it. A drop in deaths that big from a two year course of shots would be without parallel in medicine for older people. Then there is the swap. The study used epithalamin, which is an extract of pineal gland tissue. What is sold today is epitalon, a lab made four amino acid chain. They are not the same substance. For scale, a properly blinded trial of a defined thymus peptide in 1,106 people with sepsis found deaths of 23.4 percent against 24.1 percent on the dummy.
What people report
Reports, not trial results
The good
- Better sleep, credited to the pineal peptide.
- Fewer colds over a winter, credited to the thymus peptide.
- A general sense of feeling well during a course.
The bad
- Nothing measurable, which is what most people find when they check bloodwork before and after.
- Sore shot sites.
- You cannot check the claimed benefit yourself. The study measured death rates over years.
- These are tissue extracts, not single defined molecules, so batches are not guaranteed to match.
Where these come from: Longevity and peptide forums and seller pages. People talking, about an outcome no individual can judge in themselves.
My bottom line
I am not dismissing it and I am not buying it. Somebody did study the combination, which is more than any other blend here can say. But the way they studied it does not support the size of the claim. If you are buying epitalon because of those numbers, you are buying a different substance from the one in the study.
An opinion, not a finding. I am a coach, not a doctor.
Overview
The rare combination in this batch that was actually studied as a combination: 266 elderly people followed for six to eight years on thymalin and epithalamin, where the group given both had a 2.5-fold lower mortality rate than controls and a subgroup treated annually for six years had a 4.1-fold reduction. The trial was unblinded, single-centre, from one research group, has never been replicated, and the pineal component in it was a gland extract rather than the synthetic tetrapeptide sold today.
This page has to do something unusual: report an extraordinary claim from a real combination study and then say precisely why it is not settled.
The study. Researchers at the St Petersburg Institute of Bioregulation and Gerontology and the Institute of Gerontology in Kiev assessed thymic and pineal peptide bioregulators, thymalin and epithalamin, in 266 elderly and older persons over six to eight years, with the bioregulators applied during the first two to three years of observation. Acute respiratory disease incidence fell 2.0 to 2.4-fold, with reduced incidence of clinical ischaemic heart disease, hypertension, deforming osteoarthrosis and osteoporosis compared with control. Mortality fell 2.0 to 2.1-fold in the thymalin group, 1.6 to 1.8-fold in the epithalamin group and 2.5-fold in the group given both. A separate group treated with both annually for six years had a mortality rate 4.1 times lower than control.
If those numbers held up, they would be the largest longevity result in this database by a wide margin. Here is why they are not treated that way.
The report is from a single research group publishing in a journal it has used extensively for its own programme. There is no indication of blinding or of randomised allocation in the published description. Control group selection is not described in a way that rules out healthier people being assigned to treatment. No independent group anywhere has attempted a replication in the two decades since. And a mortality reduction of that size from a two to three year course of injections would be an effect without precedent in geriatric medicine, which is a reason for more scrutiny rather than less.
The identity problem is separate and important. The study used epithalamin, a peptide extract of the pineal gland. What is sold today as epitalon is a synthetic tetrapeptide, alanine-glutamate-aspartate-glycine, developed later as a defined molecule. They are not the same substance, and a person buying epitalon on the strength of the epithalamin result has substituted one thing for another. Thymalin is likewise a thymic extract rather than a single defined peptide.
For comparison on what a modern trial of a thymic peptide looks like: thymosin alpha-1, a defined 28 amino acid thymic peptide, was tested in 1,106 adults with sepsis in a double-blind placebo-controlled phase 3 trial and 28 day mortality was 23.4% against 24.1% on placebo.
Mechanism of action
Thymalin is a peptide complex extracted from calf thymus and is claimed to restore thymic-dependent immune function. Epithalamin is a pineal peptide extract; epitalon is the synthetic tetrapeptide derived from that programme and is claimed to act on pineal function, melatonin rhythm and telomerase. The mechanistic literature is largely from the originating research programme, and a 2025 review summarises the epitalon claims from cell and animal work rather than from controlled human trials.
Human evidence
There is a real combination study with extraordinary numbers, from one group, unblinded, never replicated, using a pineal extract rather than the tetrapeptide now sold.
- The combination: studied, in 266 elderly people over six to eight years, which makes this the only entry in this batch with its own combination data.
- Reported mortality reduction of 2.5-fold with both peptides, and 4.1-fold in a subgroup given both annually for six years.
- Reported 2.0 to 2.4-fold reduction in acute respiratory disease incidence.
- No blinding or randomised allocation is described, and control group construction is not detailed.
- No independent replication in the two decades since publication.
- The pineal component was epithalamin, a gland extract, not the synthetic tetrapeptide epitalon sold today.
What this does not tell you: An unblinded single-group report of a mortality halving from a short course of injections is the kind of claim that requires independent replication before it can be treated as a finding. The absence of any attempt at replication is itself the most important missing piece.
What it has been measured to do
Measured in people
Goals Thymalin with epitalon has been measured for in a human being, most people first. Counts come from the study lines on this page and deliberately undercount.
- Living longer1,106 people · 2 studies · 1 found nothing
- Immune function1,106 people · 1 study · 1 found nothing
- Bone strengthno headcount stated · 1 study
- Blood pressureno headcount stated · 1 study
What people using it report
Uncontrolled and self-selected, so it cannot show that anything works. It is still the best guide on this page to what people actually do with Thymalin with epitalon, what they expect, and what goes wrong. The full account, including the negative reports, is below.
31 of the 36 indexed goals have no study of any kind behind Thymalin with epitalon
No trial, no animal work, no cell work on this page reports a result for these. That is an absence of evidence rather than evidence of absence, but it does mean anything you have been told about Thymalin with epitalon and one of these did not come from a study cited here.
Reading the research record
The right stance here is neither dismissal nor acceptance. A combination was studied, over a long period, with mortality as an endpoint, which is more than any other blend in this batch can say. The methodological description does not support the strength of the conclusion, and the field has not tried to check it.
The substitution problem is what most buyers get wrong. The mortality paper used epithalamin, a peptide extract of pineal tissue. What is sold under the name epitalon is a synthetic tetrapeptide developed later. A person buying epitalon because of the 2003 mortality figures has bought a different substance from the one in the study, and nobody has shown the two behave alike.
The contrast with thymosin alpha-1 is the cleanest available calibration. A defined thymic peptide with a manufacturer behind it went into a 1,106-patient double-blind placebo-controlled trial and came out with a hazard ratio of 0.99. That is how a thymic peptide performs when the trial design removes the things that inflate uncontrolled results.
The evidence, charted
Fig. 1a · evidence scale
1,106people, across 1 human study cited here
- 2025 · BMJ1,106100%
The whole total is one study of 1,106. Counts are the enrollment each human citation on this page states, which includes observational cohorts where nobody was given the compound. 1 further human citation states no participant count and is not counted here. Studies still recruiting are excluded, and only studies cited on this page are counted.
Fig. 1b · evidence mix
2 of 3 citations here are human work, the rest is not.
- Human · given to people267%
- Review · summarises other work133%
Counted from the citation list on this page, typed as this page types it. It understates any literature larger than the sources we cite, and a review counts once however many studies it covers.
Fig. 2 · evidence over time
Citations here span just two years, 2003 and 2025.
Too few distinct publication years on this page to plot as a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 5 · molecular identity
- Modality
- Blend
- Molecular weight
- Not on file
- Half-life
- Stated in words, not a number
- Sequence length
- None on file
see the exact wording below
Half-life as stated on file: Not defined. No pharmacokinetic study of either preparation has been published in a Western journal.
No amino acid sequence is on file for Thymalin with epitalon, which is expected: a blend is not built from residues.
Fig. 6 · what is in the vial
No mass split can be drawn for this blend
Sellers do not publish a consistent vial size for Thymalin with epitalon, so the share of each component is not knowable from the outside. Splitting the bar evenly would invent the number this page exists to question.
Component list from the product labels we hold. Amounts are label mass, never a dose.
Key studies & citations
- Human2003
Peptides of pineal gland and thymus prolong human life
266 elderly and older persons assessed over six to eight years, with thymalin and epithalamin applied during the first two to three years. Acute respiratory disease incidence fell 2.0 to 2.4-fold, with reduced clinical ischaemic heart disease, hypertension, deforming osteoarthrosis and osteoporosis against control. Mortality fell 2.0 to 2.1-fold with thymalin, 1.6 to 1.8-fold with epithalamin and 2.5-fold with both, and a separate group treated with both annually for six years had a 4.1-fold lower mortality rate. Single group, no described blinding or randomisation, never replicated.
Neuro Endocrinology Letters - Review2025
Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties
A review of the claimed properties of the synthetic pineal tetrapeptide epitalon, drawing on cell and animal work and the Russian bioregulator literature. It describes a tetrapeptide, which is a different substance from the pineal gland extract epithalamin used in the 2003 mortality study.
International Journal of Molecular Sciences - Human2025
The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial
1,106 adults with sepsis, 22 centres, double blinded and placebo controlled. 28 day all cause mortality was 23.4% on thymosin alpha-1 and 24.1% on placebo, hazard ratio 0.99, p = 0.93. Included here as the contrast: this is what a defined thymic peptide looks like when tested under modern conditions, and the result was null.
BMJ
What users report
Self-reported experiences, not evidence. Nothing below was measured under controlled conditions, and reports like these cannot separate a real effect from placebo, from the training or diet change that accompanied it, or from what the product actually contained. They are here because knowing what people describe, including what goes wrong, is worth reading alongside the studies.
- Better sleep, attributed to the pineal peptide.
- Fewer colds over a winter, attributed to the thymic peptide.
- A general sense of wellbeing during a course.
- Nothing measurable, which is the usual outcome for anyone who checks bloodwork before and after.
- Injection site soreness.
Sources: Longevity and peptide forums including r/peptides, and vendor pages. Uncontrolled self-reports on outcomes that cannot be assessed by an individual over a short period, since the claimed endpoint of the original study was mortality.
Frequently asked questions
Was this combination actually studied?
Yes, which makes it unusual. 266 elderly people were followed for six to eight years, and the group given both peptides was reported to have a 2.5-fold lower mortality rate than controls, with 4.1-fold in a subgroup treated annually for six years.
Should I believe those numbers?
Not without replication. The report is from a single research group, describes no blinding or randomised allocation, does not detail how controls were selected, and has never been independently repeated in two decades. A mortality halving from a short course of injections would be unprecedented in geriatric medicine.
Is epitalon the same as epithalamin?
No. The study used epithalamin, a pineal gland peptide extract. Epitalon is a synthetic tetrapeptide developed later. Buying epitalon on the strength of that study means substituting one substance for another.
What happens when a thymic peptide is tested properly?
The most recent attempt was thymosin alpha-1 in 1,106 adults with sepsis, double blinded and placebo controlled. 28 day mortality was 23.4% against 24.1% on placebo, a hazard ratio of 0.99.
Are these single molecules?
Thymalin and epithalamin are peptide extracts of thymus and pineal tissue rather than defined single peptides, which is part of why the results are hard to replicate and part of why batch to batch consistency is not established.